Free tool
FAERS Monitor: Anktiva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761336 or its brand name (Anktiva, Nogapendekin Alfa Inbakicept-Pmln). Reports on generic versions are filed under their own applications.
Reports
49
Serious
23
47% of reports
Hospitalization
7
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia10
- chills7
- pyrexia6
- dysuria5
- pollakiuria5
- anaemia4
- bladder pain4
- nausea4
- urinary tract infection4
- drug ineffective3
- haematuria3
- abdominal distension2
- abdominal pain lower2
- arthralgia2
- bladder cancer recurrent2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 26 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,110 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bladder cancer recurrent | 2 | 863.7 | 221.9 | 967 |
| bladder painSignal | 4 | 541.5 | 211.6 | 1,650 |
| dysuriaSignal | 5 | 58.3 | 25.4 | 228 |
| pollakiuriaSignal | 5 | 51.5 | 22.4 | 200 |
| haematuriaSignal | 3 | 37.6 | 12.6 | 74 |
| abdominal pain lower | 2 | 34.0 | 8.7 | 35 |
| neutropeniaSignal | 10 | 31.6 | 18.2 | 268 |
| chillsSignal | 7 | 25.6 | 12.9 | 143 |
| urinary tract infectionSignal | 4 | 10.1 | 3.9 | 24 |
| anaemiaSignal | 4 | 9.0 | 3.5 | 21 |
| abdominal distension | 2 | 8.2 | 2.1 | 7 |
| pyrexiaSignal | 6 | 7.4 | 3.5 | 28 |
| nausea | 4 | 2.2 | 0.8 | 2 |
| arthralgia | 2 | 2.1 | 0.5 | 0 |
| drug ineffective | 3 | 1.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.